Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 15/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.45 |
| ▸ | FDFT1 | P37268 | 2/20 | 0.39 |
| ▸ | CA12 | O43570 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9790749 | 0.88 | FDPS (1.00) | FDPSCCNE1CDK2CDK5FDFT1 | |
| SCHEMBL7163557 | 0.85 | FDPS (1.00) | FDPSCCNE1CDK2CDK5FDFT1 | |
| SCHEMBL7164309 | 0.79 | FDPS (1.00) | FDPSCA12CA1MMP8 | |
| SCHEMBL9790756 | 0.78 | FDPS (0.97) | FDPSCA12CA1MMP8 | |
| SCHEMBL9790652 | 0.76 | FDPS (1.00) | FDPSCCNE1CDK2CDK5FDFT1 | |
| SCHEMBL9790803 | 0.76 | FDPS (0.66) | FDPSFDFT1MMP8 | |
| SCHEMBL12144621 | 0.73 | FDPS (0.58) | FDPSCCNE1CDK2CDK5 | |
| SCHEMBL6220901 | 0.72 | FDPS (0.56) | FDPSCCNE1CDK2CDK5 | |
| SCHEMBL23213713 | 0.71 | CCNE1 (0.66) | FDPSCCNE1CDK2CDK5 | |
| SCHEMBL9790811 | 0.71 | FDPS (0.61) | FDPSCCNE1CDK2CDK5MMP8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | claimed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | claimed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | claimed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | claimed |
| US-5057505-A | Treatment of illnesses attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | claimed |
| US-6255288-B1 | THERAPY FOR BONE DISORDERS | NOVARTIS CORPORATION | 2001-07-03 | — | — | US | disclosed |
| EP-0600834-A1 | Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing | CIBA-GEIGY AG (CH) | 1994-06-08 | — | — | EP | disclosed |
| US-5296475-A | Methanediphosphonic acids and crown compounds for treatment of bone disorders or hypercalcemia | CIBA-GEIGY CORPORATION (US) | 1994-03-22 | — | — | US | disclosed |
| EP-0550385-A1 | Oral pharmaceutical compositions containing derivatives of methane-diphosphonic acid and 18-crown-6 ethers | CIBA-GEIGY AG (CH) | 1993-07-07 | — | — | EP | disclosed |
| US-5133972-A | TOPICALLY ADMINISTRABLE PHARMACEUTICAL PREPARATIONS | CIBA-GEIGY CORPORATION (US) | 1992-07-28 | — | — | US | disclosed |
| US-5057505-A | Treatment of illnesses attributed to calcium metabolism disorders | CIBA-GEIGY CORPORATION (US) | 1991-10-15 | — | — | US | disclosed |
| EP-0407344-A2 | Pharmaceutical preparation for topical application | CIBA-GEIGY AG (CH) | 1991-01-09 | — | — | EP | disclosed |